a transmembrane domain, and a large extracellular domain. The extracellular domain is responsible for the enzymatic cleavage of the substrates and binding to its ligands including fibronectin and ADA. DPP-4 inactivates GLP-1 by removing N-terminal dipeptide His7Ala8 from active...
In contrast, GLP-1 receptor (GLP-1R) activation has been shown to confer both renal and cardiovascular protection, though its relationship with CKD and CKD with myocardial ischemia/reperfusion (MI/R) remains poorly understood. Here, we investigated changes in renal and myocardial GLP-1R expression...
GLP-1 is produced by ileal L-cells rapidly after ingestion of a meal and exerts its effects through: i) stimulation of insulin release; ii) inhibition of glucagon release; iii) slowing of gastric emptying. GLP-1, together with the glucose-dependent insulinotropic peptide (GIP)-1, belongs to...
Second, I examined the effect of sitagliptin and GLP-1 receptor agonist exendin 4 on EDRs in hypertension. The major novel findings of this part include: (1) two-week oral administration of sitagliptin to SHRs lowered systolic blood pressure and improved renal blood flow in vivo; (2) ...
Additionally GLP-1 inhibits pancreatic α cells, leading to a decrease in glucagon production. Increased insulin and decreased glucagon result in a reduction in glucose output by the liver. Together, this increase in insulin and decrease in glucagon result in a net decrease in blood glucose....
Dipeptidyl peptidase-4 (DPP-4) inhibitors are glucose-lowering drugs for type 2 diabetes mellitus (T2DM). We investigated whether evogliptin® (EVO), a DPP-4 inhibitor, could protect against diabetic cardiomyopathy (DCM) and the underlying mechanisms.
Eleven studies with a total number of 1,019,476 participants with T2DM were included in this analysis whereby 480,549 patients were assigned to SGLT-2 inhibitors and 538,927 patients were assigned to DPP-4 inhibitors. Result of this analysis showed SGLT-2 inhibitors to be associated with a ...
The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system. Diab Vasc Dis Res 2014;11(5):306-323.Schernthaner G, Mogensen CE, Schernthaner GH. The effects of GLP-1 analogues, DPP-4 inhib- itors and SGLT2 inhibitors on the renal system. Diab Vasc ...
The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system. Diab Vasc Dis Res. 2014;11(5):306-23.Schernthaner G, Mogensen CE, Schernthaner GH. The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system. Diab Vasc Dis ...
dihydromyricetin; exercise; GLP-1; gut microbiota; cAMP; DPP-41. Introduction It has been estimated that physical inactivity is the fourth leading cause of death in the world, accounting for 6% of all deaths [1]. Exercise is widely regarded as the most cost-effective and efficient method of...